核受体aaa_图文.pdfVIP

0031-6997/06/5804-685–704$20.00 PHARMACOLOGICAL REVIEWS Vol. 58, No. 4 Copyright © 2006 by The American Society for Pharmacology and Experimental Therapeutics 50423/3156338 Pharmacol Rev 58:685–704, 2006 Printed in U.S.A Overview of Nomenclature of Nuclear Receptors PIERRE GERMAIN, BART STAELS, CATHERINE DACQUET, MICHAEL SPEDDING, AND VINCENT LAUDET Department of Cell Biology and Signal Transduction, Institut de Genetique et de Biologie Moleculaire et Cellulaire, Institut National de la Sante´ et de la Recherche Me´dicale U596, Illkirch, France (P.G.); Institut Pasteur de Lille, Institut National de la Sante´ et de la Recherche Me´dicale U545, Universite´ de Lille II, Lille, France (B.S.); Experimental Sciences Institute of Research Servier, Suresnes, France ´ (C.D., M.S.); and Laboratoire de Biologie Moleculaire de la Cellule, BioSciences Lyon-Gerland, Ecole Normale Supe´rieure de Lyon, Lyon, France (V.L.) Abstract——Nuclear receptor pharmacology has, to going through the drug discovery development pro- a certain extent, led the way, compared with other cess, then initial screens using reconstituted systems receptor systems, in the appreciation that ligands may may not show the appropriate pharmacology, simply exert very diverse pharmacology, based on their indi- because the required stoichiometry of corepressors vidual chemical structure and the allo